Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
@vculiver.bsky.social
The Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University is revolutionizing global health through innovative liver research. 804-828-5066.
🚨NEW IN #NEJM🚨ESSENCE #VCU-led researchers report weekly injections of #semaglutide resolved steatohepatitis without worsening of fibrosis in 63% of #MASH patients getting weekly semaglutide injections, across 37 countries. #liver www.nejm.org/doi/full/10....
Screening for MASLD by at 29th Annual Virginia Liver Symposium by @juanpabloarab.bsky.social @vculiver.bsky.social 🌎 prevalence of MASLD 30% ⬆️ risk progression with DM, HTN, obesity, menopause Screen for 🍷 ♻️ Putative connection between MASLD, CVD, CKD
Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas @juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social
ASCI member Jasmohan S. Bajaj @jasmohanbajaj et al. @VCU_liver show that fecal transplant ameliorates a source of cirrhosis progression:
JCI Insight - Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with FMT
Research LetterIn-Press PreviewHepatologyMicrobiology Open Access | 10.1172/jci.insight.186649
insight.jci.org
🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social
Paul Sax@paulsaxmd.bsky.social · 2y agoBefore reading this excellent perspective, I had no idea that the data supporting the use of antibiotic prophylaxis for SBP were so weak. Really time to re-think this "standard-of-care" practice! Highly recommended. #IDSky doi.org/10.1093/cid/...
🙏 for highlighting our commentary @cidjournal.bsky.social Need to re-evaluate these practices due to ⬆️ - #amr burden - C difficile & #antibiotic adverse events - costs #liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social
Timothy Li@drtimothyli.bsky.social · 2y agoRethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis ➡️Standard of care since the 1990s and is currently recommended by several major GI societies ➡️Weak supporting evidence ➡️No clear mortality benefit doi.org/10.1093/cid/... #IDSky
Check out @nytimes.com interview of experts re: #wellness my tip? Coffee for the win!! Liver brain and microbes all benefit from this Check it out below www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social
Gastroenterology>General Hepatology FDA Issues Safety Alert on Liver Disease Drug. — Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis. by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...
FDA Issues Safety Alert on Liver Disease Drug
Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis
medpagetoday.com
Taking a first step on Bsky ... here's our team and colleagues at #VCU's Division of GI, Hep and Nutrition. #liversky #gastrosky
